-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Awarded the Title of “Shijiazhuang City Model Enterprise for Contract Compliance and Creditworthiness”
Category:
发布时间：2023-06-16
【概要描述】
Recently, the Shijiazhuang Municipal Administration for Market Regulation announced gratifying news: Shijiazhuang Sihua Pharmaceutical Co., Ltd. has been recognized as a “Shijiazhuang City Model Enterprise for Contract Compliance and Creditworthiness for the 2021–2022 Period” thanks to its robust corporate credit management system and excellent track record in contract performance and credit standing.
Recently, the Shijiazhuang Municipal Administration for Market Regulation announced gratifying news: Shijiazhuang Sihua Pharmaceutical Co., Ltd. has been recognized as a “Shijiazhuang City Model Enterprise for Honoring Contracts and Valuing Credit for the 2021–2022 Period” thanks to its robust corporate credit management system and excellent track record in contract performance and creditworthiness.
According to reports, the “Shijiazhuang City Model Enterprise for Contract Compliance and Creditworthiness” selection initiative is organized by the Shijiazhuang Municipal Administration for Market Regulation. The initiative aims to promote corporate credit development, enhance enterprises’ brand image, and provide them with robust qualification and resource advantages in market competition.
As a key pillar enterprise in Shijiazhuang’s biopharmaceutical industry, Shijiazhuang Sihua Pharmaceutical upholds integrity as the cornerstone of its corporate ethos, regarding “integrity-based management” as a core competitive advantage for business operations and development. The company continuously strengthens contract management, reinforces its credit foundation, cultivates a culture of corporate integrity, builds a reputable brand rooted in trustworthiness, and elevates its overall level of integrity-building efforts. In doing so, it translates the principles of “integrity-driven operations” and “faithful performance of contractual obligations” into concrete practices across all aspects of its business management.
The successful development of robust corporate credit has enabled the company to emerge as a leader in the industry’s high-quality development, earning widespread acclaim and respect from both the market and society. To date, it has garnered a series of prestigious awards, including “National Model Enterprise for Contract Compliance and Creditworthiness,” “Hebei Provincial Government Quality Award,” “AAA-Credit Enterprise of China,” and “Hebei Provincial Integrity Enterprise.”
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091